Hinge Health is executing a compelling growth inflection, with revenue accelerating 53% year-over-year to $212.8M in Q2 2026 and gross margins expanding to 86.4%, signaling strong scalability. The company has achieved a pivotal profitability milestone, swingin...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 53% YoY in Q2 2026, reaching $212.8M, while gross margin expanded to 86.4% and operating margin swung to +19.0% from -4.2% a year earlier, demonstrating strong operating leverage.
Hinge Health leverages AI, wearable devices, and expert clinicians to deliver personalized, evidence-based care, improving member outcomes and experiences.
Needham estimates Hinge Health could re-achieve 'Rule of 50+' status, combining high growth rates and profit margins exceeding 50%.
The company aims to revolutionize healthcare by scaling and automating care delivery through advanced technology, enhancing outcomes and reducing costs.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $0.59-4.1% vs $0.61 | $213M+5.6% vs $201M |
Q2 2026 May 5, 2026 | $0.45+15.4% vs $0.39 | $182M+5.9% vs $172M |
Q1 2026 Feb 10, 2026 | $0.49+1125.0% vs $0.04 | $171M+9.0% vs $157M |
Q4 2025 Nov 4, 2025 | $0.34+41.7% vs $0.24 | $154M-1.6% vs $157M |
Hinge Health Inc. (NYSE: HNGE - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $97.95 and last traded at $94.3050, with a volume of 157292 shares traded. The stock had previously closed at $92.45. Analyst Ratings Changes Several brokerages recently issued reports on HNGE. Barclays
The healthcare sector has performed fairly well so far in 2026 due to several factors: GLP-1 medications continue to drive new business and interest, while groundbreaking AI applications help enhance and accelerate the drug discovery process. On top of that, potential mergers and acquisitions activity, as big pharmaceutical companies face a major patent cliff, could provide opportunities for new firms to stand out.
Hinge Health Inc. (NYSE: HNGE - Get Free Report) President James Pursley sold 33,000 shares of Hinge Health stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $94.14, for a total transaction of $3,106,620.00. Following the completion of the sale, the president owned 666,909 shares of
CorVel (NASDAQ: CRVL - Get Free Report) and Hinge Health (NYSE: HNGE - Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk. Insider and Institutional Ownership 51.4% of CorVel shares
Benchmark HNGE against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Hinge Health, Inc. (HNGE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $97.94 | $7.58B | -18.87 | 50.58% | -89.86% | -132.86% | — | |
| $33.44 | $1.52B | 754.85 | 6.53% | 3.13% | 3.13% | — | |
| $5.67 | $1.02B | -4.97 | -1.54% | -7.13% | -13.08% | — | |
| $29.30 | $6.54B | 57.45 | 59% | -5.51% | -30.03% | — | |
| $28.50 | $5.33B | 29.08 | 13.05% | 25.48% | 16.95% | — | |
| $12.82 | $218.05M | -2.15 | -1.98% | -35.75% | -31.57% | — |
Hinge Health, Inc. (HNGE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Hinge Health, Inc. (HNGE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jun 9, 2026·SEC
Jun 4, 2026·SEC
Mar 3, 2026·SEC
Get notified when HNGE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Hinge Health, Inc. (HNGE) stock FAQ — growth, dividends, profitability & financials explained
Hinge Health, Inc. (HNGE) reported $720.1M in revenue for fiscal year 2025. This represents a 146% increase from $292.7M in 2023.
Hinge Health, Inc. (HNGE) grew revenue by 50.6% over the past year. This is strong growth.
Yes, Hinge Health, Inc. (HNGE) is profitable, generating $109.1M in net income for fiscal year 2025 (-89.9% net margin).
Hinge Health, Inc. (HNGE) has a return on equity (ROE) of -132.9%. Negative ROE indicates the company is unprofitable.
Hinge Health, Inc. (HNGE) generated $287.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
